Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

Ulrike Harre,1 Dan Georgess,2 Holger Bang,3 Aline Bozec,1 Roland Axmann,1 Elena Ossipova,4 Per-Johan Jakobsson,4 Wolfgang Baum,1 Falk Nimmerjahn,5 Eszter Szarka,6 Gabriella Sarmay,6 Grit Krumbholz,7 Elena Neumann,7 Rene Toes,8 Hans-Ulrich Scherer,8 Anca Irinel Catrina,3 Lars Klareskog,3 Pierre Jurdic,2 and Georg Schett1

1Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany. 2Institut de Génomique Fonctionnelle de Lyon, Université de Lyon, and CNRS, Ecole Normale Superieure de Lyon, Lyon, France. 3Orgentec Diagnostika, Mainz, Germany. 4Rheumatology Unit, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden. 5Department of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany. 6Department of Immunology, Eotvos Lorand University, Budapest, Hungary. 7Department of Rheumatology, University of Giessen, Bad Nauheim, Germany. 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands.

Autoimmunity is complicated by bone loss. In human rheumatoid arthritis (RA), the most severe inflammatory joint disease, autoantibodies against citrullinated proteins are among the strongest risk factors for bone destruction. We therefore hypothesized that these autoantibodies directly influence bone metabolism. Here, we found a strong and specific association between autoantibodies against citrullinated proteins and serum markers for osteoclast-mediated bone resorption in RA patients. Moreover, human osteoclasts expressed enzymes eliciting protein citrullination, and specific N-terminal citrullination of vimentin was induced during osteoclast differentiation. Affinity-purified human autoantibodies against mutated citrullinated vimentin (MCV) not only bound to osteoclast surfaces, but also led to robust induction of osteoclastogenesis and bone-resorptive activity. Adoptive transfer of purified human MCV autoantibodies into mice induced osteopenia and increased osteoclastogenesis. This effect was based on the inducible release of TNF-α from osteoclast precursors and the subsequent increase of osteoclast precursor cell numbers with enhanced expression of activation and growth factor receptors. Our data thus suggest that autoantibody formation in response to citrullinated vimentin directly induces bone loss, providing a link between the adaptive immune system and bone.

Introduction

RA affects about 1% of the population worldwide and is one of the most destructive diseases in humans (1, 2). Current concepts suggest that RA emerges by complex gene-environment interactions involving HLA and other genes, as well as in response to environmental factors (3, 4). Smoking, for instance, elicits cellular responses, such as posttranslational modification of proteins; among these, citrullination is considered a key stress response of cells to noxious stimuli. Citrullination is achieved by enzymes called peptidylarginine deiminases (PADs), which metabolize the amino acid arginine into citrulline (5). Smoking induces citrullination of the bronchial epithelium. In addition, bacteria involved in periodontitis, such as Porphyromonas gingivalis, also strongly induce protein citrullination (3, 6). Interestingly, more than 70% of patients with RA show a breach in tolerance for citrullinated proteins eliciting an anti–citrullinated protein antibody (ACPA) response (7, 8). This ACPA response is highly specific for RA and not found in other forms of autoimmune disease. The formation of ACPAs is closely related to certain HLA genotypes, like the shared epitope and environmental factors (such as smoking). Interestingly, ACPAs emerge years before the onset of clinically overt RA, which suggests that autoimmunity precedes inflammation in RA (9).

It has always been stunning how effectively RA destroys bone. If the inflammatory disease process is not treated early and effectively, then bone erosions emerge after a few months of disease and lead to the destruction of the entire joint (10). Moreover, osteoporosis emerges fast in RA and affects even patients with early disease, leading to an increased fracture risk later on. Inflammation appears to be a key risk factor for bone loss in RA. Surrogate markers for high inflammatory disease activity, such as high C-reactive protein levels, are predictive for local and systemic bone loss (11). The negative influence of inflammation on bone reflects the tight interactions between the immune system and the skeleton, which have recently led to a new research field termed osteoimmunology (12). Apart from inflammatory disease burden, however, the strongest risk factor for bone loss is the presence of ACPAs. Several studies have shown that ACPAs are among the strongest predictors for bone-erosive disease in RA, strongly suggesting a direct link between autoantibody response in RA and the ability of the disease to elicit structural bone damage (13–16). We therefore hypothesized that the main autoantibody response in RA, namely that of ACPAs, directly influences bone homeostasis. As bone resorption is considered to be among the leading mechanisms of bone loss in RA, we studied whether ACPAs influence bone resorption.

Results

ACPAs are associated with increased bone resorption in patients with RA. Given that the presence of ACPAs in RA patients is associated with bone loss and our hypothesis that ACPAs themselves can precipitate bone loss by influencing bone metabolism, we first sought to
determine whether the presence of ACPAs in RA patients is linked to altered bone metabolism. We investigated serum samples from RA patients with ACPAs for markers of bone resorption and bone formation and compared the results with those of RA patients without ACPAs as well as normal controls. To minimize bias, we focused on newly diagnosed RA patients without concomitant treatment of glucocorticoids or other immunosuppressants. We also carefully matched the groups (ACPA-positive/rheumatoid factor–negative RA, ACPA-negative/rheumatoid factor–positive RA, ACPA-negative/rheumatoid factor–negative RA, and healthy controls) for age and sex as well as for disease activity and disease duration. When analyzing C-terminal cleavage products for collagen type I (CTXI) as a marker of bone resorption, we found significantly higher CTXI in ACPA-positive patients than in all other groups ($P < 0.01$; Figure 1A). The influence of ACPA on bone resorption in RA patients was even more evident when ACPA titers were correlated with CTXI levels. Even patients with low ACPA levels (<200 U/ml) had higher CTXI than did RA patients without ACPA (Figure 1B). Moreover, CTXI level was related to ACPA titer, as patients with modest and high ACPA levels showed a dose-dependent increase of bone resorption (Figure 1B). Similar results were observed with other markers of bone resorption, such as the serum level of the osteoclast-derived enzymes tartrate-resistant acid phosphatase 5b (TRAP5b) and cathepsin K. RA patients with ACPA showed significantly higher levels of these markers (Figure 1, C and D). In contrast, bone formation, which was measured by bone alkaline phosphatase, was the same among RA patients with or without ACPA, with levels tending toward lower than those of healthy controls. These data support the notion that the presence of ACPA is associated with bone loss in RA.

Isolation of ACPAs with specificity to mutated citrullinated vimentin from human RA patients. We consequently sought to determine the mechanism by which ACPAs are linked to enhanced bone resorption, hypothesizing that these autoantibodies directly stimulate the differentiation of bone-resorbing cells. To test this concept, we first had to exactly define the ACPA responses in human RA patients that are strongly linked to bone resorption. We therefore affinity-purified ACPAs from 3 individual RA patients with very high ACPA responses (>1,000 U) and high levels of bone resorp-
We decided to isolate human ACPAs with specificity to mutated citrullinated vimentin (MCV), as these autoantibodies are highly specific for RA (17, 18), and vimentin is expressed by mononuclear cells and osteoclasts (19). By using a CNBr-sepharose column loaded with MCV, we were able to purify ACPAs and retain — and even enrich — their strong reactivity to MCV (Figure 2A). Moreover, we also cleaved the affinity-purified ACPAs with pepsin to receive F(ab′)2 fragments, which were retained high reactivity against MCV but lacked the Fc portion (Figure 2A).

Western blot analysis of the isolated affinity-purified human ACPAs against MCV (referred to herein as MCV-ACPAs) on naive and PAD-treated HeLa cells showed exclusive specificity to citrullinated vimentin, but not to noncitrullinated vimentin, after PAD treatment (Figure 2B). When analyzing binding to citrullinated and noncitrullinated protein extracts from different subcellular compartments, we observed that MCV-ACPAs particularly bound to the membrane fraction and, to a lesser extent, to the nuclear and cytosolic fractions, but exhibited virtually no binding to the
actin-containing cytoskeletal compartment (Figure 2B). Moreover, MCV-ACPAs not only showed specificity to peptides from citrullinated vimentin, in contrast to peptides from noncitrullinated vimentin, but also did not recognize citrullinated peptides from other proteins, like CTXI and fibrinogen (Figure 2C) as well as GFAP and neurofascin (data not shown). The cross-reaction of MCV-ACPAs was only observed with citrullinated peptides of the epithelial protein fillagrin.

Analysis of the presence of sugar moieties by enzyme-linked lectin assay showed glycosylation of MCV-ACPAs, which was sensitive to neuraminidase digestion (Figure 2D). Analysis of the epitope recognition pattern of isolated MCV-ACPAs by testing binding to a peptide library spanning the entire citrullinated vimentin protein revealed a dominant N-terminal epitope at amino acid position 56–77 (Figure 2E).

Osteoclasts express enzymes involved in citrullination and show citrullination of vimentin. We next validated the expression of the target of MCV-ACPAs in the osteoclast lineage. Citrullination of proteins depends on the presence of the enzyme PAD, which metabolizes arginine into citrullin. Among the different PAD enzymes, only PAD2 and PAD4 were expressed in the monocyte lineage and were also found in osteoclast precursor cells at the mRNA and protein levels (Figure 3, A–C). Whereas PAD4 expression decreased with further differentiation of osteoclast precursors into osteoclasts, PAD2 expression increased during this process (Figure 3C). Furthermore, vimentin expression increased during osteoclast differentiation (Figure 3D). When using a commercially available antibody against citrullinated vimentin or MCV-ACPAs, we observed that expression of citrullinated vimentin also increased during osteoclast differentiation (Figure 3E and F), which suggests that the target for MCV-ACPAs is indeed inducibly expressed in the osteoclast lineage. These data suggested strong binding of MCV-ACPAs to cells of the osteoclast lineage, particularly to cells in more advanced osteoclastogenic differentiation state with increased citrullination of vimentin.

Finally, these data were validated by performing mass spectrometry of citrullinated proteins from various differentiation stages (days 0, 2, 5, 8, 10, and 14) of osteoclast lineage cells. Only 3 proteins (vimentin, actin, and α-2-HS-glycoprotein) showed consistent citrullination during the process of osteoclast differentiation; of these, vimentin was the only one specifically citrullinated at more advanced differentiation stages (i.e., after day 5). Moreover, the
citrullinated peptide sequence of vimentin detected by mass spectrometry (KVELQELNDXANYIDKV; citrullin denoted by X) was colocalized with the citrullinated epitope in the N-terminal part of vimentin recognized by the ACPA.

**MCV-ACPAs induce osteoclastogenesis and bone resorption.** Based on our clinical observations and the experimental evidence for vimentin citrullination in osteoclasts, we hypothesized that ACPAs can directly stimulate osteoclast-mediated bone resorption. We therefore sought to determine whether ACPAs can trigger osteoclastogenesis, testing the ability of ACPA-containing serum and MCV-ACPAs to stimulate osteoclastogenesis. Using laser scanning microscopy, we found the plasma membrane and cytoplasm of osteoclasts to be stained by MCV-ACPAs (Figure 4A), indicative of citrullinated vimentin expression. Expression of citrullinated

---

**Figure 4**

MCV-ACPAs stimulate osteoclastogenesis. (A) Laser scanning microscopy of 2-mm osteoclast sections showing binding of MCV-ACPAs. Left: green, MCV-ACPAs staining for citrullinated vimentin; red, phalloidin staining for actin; blue, DAPI staining for the nucleus. Right: green, vimentin staining; red, MCV-ACPAs staining for citrullinated vimentin; blue, DAPI staining for the nucleus. Arrowheads indicate surface staining for citrullinated vimentin. (B) Osteoclastogenesis (n = 3) induced by 10 ng/ml MCSF, 1 ng/ml RANKL, and different concentrations of MCV-ACPAs and of IgG fractions deprived of ACPAs (eluate) in the presence of MCSF and RANKL. N.Oc, number of osteoclasts. (C) Resorption pit assay (n = 3) with different concentrations of MCV-ACPAs and of IgG fractions deprived of ACPA. (D) Assessment of resorption index (n = 3) by transposing a defined number of osteoclasts on bone slices and measuring the resorption pit size per single osteoclast. Control indicates no antibody addition. Original magnification, x20 (A); x100 (A, enlarged view); x10 (B and D). Scale bars: 100 μm. *P < 0.05.
The vimentin was not colocalized to the actin cytoskeleton, nor, interestingly, to noncitrullinated vimentin. Importantly, when performing osteoclast differentiation assays with MCSF and RANKL, we observed that addition of ACPA-containing serum (data not shown) or MCV-ACPAs increased the formation of osteoclasts (Figure 4B). In contrast, RA serum without ACPAs, as well as IgG (isolated from ACPA-positive serum samples) deprived of MCV-ACPAs, did not stimulate MCSF/RANKL-mediated osteoclastogenesis. Furthermore, osteoclast differentiation was enhanced by ACPAs, since TRAP-positive mononuclear cells appeared earlier in ACPA-challenged osteoclast cultures (data not shown).

When assessing bone resorption, we found a dose-dependent increase of resorption pits in the presence of ACPA-containing serum as well as MCV-ACPAs (Figure 4C), which suggests that ACPAs induce bone resorption. These findings were consistent with the use of MCV-ACPAs or a Fab fragment of this antibody, excluding osteoclastogenesis stimulation and bone resorption by a solely Fc-mediated effect. Moreover, when noncitrullinated vimentin was used as an autoantigen for antibody isolation, only low amounts of antibodies could be isolated, which (a) did not recognize citrullinated vimentin and (b) did not induce osteoclastogenesis (data not shown). Furthermore, we assessed the resorption capacity of individual osteoclasts after differentiating and transposing them on bovine bone slices. These experiments showed that ACPAs did not enhance the resorptive potential of individual osteoclasts (as measured by resorption pit size of individual osteoclasts; Figure 4D), which suggests that enhancement of overall bone resorption by ACPAs is based on enhanced differentiation and, consequently, increased numbers of osteoclasts.

**MCV-ACPAs induce systemic bone loss and osteoclast formation in vivo.** We next tested whether ACPAs can also induce bone loss in vivo. We challenged lymphocyte-deficient Rag1−/− mice with MCV-ACPAs and control IgG, then analyzed bone structure after 4 weeks by micro-CT (μCT). Analysis of bone volume relative to total volume at the tibial metaphysis showed significant reduction of trabecular bone with MCV-ACPAs compared with control IgG (Figure 5, A and B). Bone loss was based on reduced trabecular number and, consequently, lower connectivity density of trabecular bone, whereas trabecular thickness was not changed (Figure 5B). In addition, histomorphometry of trabecular bone showed a significant increase in osteoclast number along the metaphysis of ACPA-treated mice (Figure 5C), which supports the in vitro assay data and suggests that enhanced bone loss in conjunction with MCV-ACPAs is based on enhanced osteoclastogenesis and bone resorption.

**Enhanced TNF production and augmentation of the osteoclast precursor cell pool as the mechanism of bone loss by MCV-ACPAs.** To further elucidate the mechanism by which MCV-ACPAs induce bone loss in vivo, we examined systemic bone resorption and bone formation parameters. In accordance with the observed increase in osteoclasts in mice exposed to ACPAs, we found an increase in CTX1, a common measure of bone-resorptive activity, in the serum of ACPA-
challenged mice. In contrast, serum levels of osteocalcin, a marker of bone formation, were not affected (Figure 6A). Interestingly, we also found an increase in systemic levels of TNF-α in mice exposed to ACPAs (Figure 6A), although we did not find signs of arthritis, induction of which may depend on a specific susceptible genetic background, as reported previously (20). TNF-α, however, is also a major inducer of osteoclastogenesis by enhancing differentiation of osteoclasts and by trafficking of osteoclast precursors (21, 22).

Indeed, when assessing the spleens of ACPA-challenged mice, we found a significant increase of CD11b+CD14+ osteoclast precursors (Figure 6B), which has been previously shown as an effect of TNF-α on cells of the osteoclast lineage (22). Moreover, the cells expressed higher surface levels of the MSCF receptor CD115 (also known as c-Fms) and the RANKL receptor RANK, making them more susceptible to further differentiation into mature osteoclasts (Figure 6B). Accordingly, spleen cells from ACPA-challenged mice showed overall higher osteoclastogenic potential by being more sensitive to stimulation by small amounts of RANKL, as well as allowing differentiation of higher numbers of osteoclasts (Figure 6C). These in vivo results were confirmed by further in vitro obser-

Figure 6
Bone loss elicited by MCV-ACPAs is induced by TNF-mediated increase of osteoclast precursor trafficking and differentiation. (A) Serum levels (n = 5 per group) of CTX1, osteocalcin, and TNF-α in Rag1−/− mice that were left untreated or treated with control IgG or MCV-ACPAs. (B) FACS analysis (n = 5 per group) of spleen cells for the number of CD11b+CD14+ cells (osteoclast precursors) and their expression of CD115 and RANK. (C) Osteoclastogenesis assay (n = 3 per group) of spleen cells from Rag1−/− mice treated with control IgG or MCV-ACPAs with various concentrations of RANKL. TNF-α release and osteoclastogenesis assays (n = 3 per group) from spleen cells of wild-type mice treated with control IgG or MCV-ACPAs are also shown. aTNF, blockade of TNF-α by 100 ng/ml etanercept. *P < 0.05.
vations: exposure to MCV-ACPAs elicited TNF-α release from spleen cells of untreated wild-type mice and enhanced osteoclastogenesis in the presence of M-CSF and RANKL, an effect that was blocked by TNF-α inhibition (Figure 6C).

Discussion

The present study provides a link between immune system and bone. We showed that autoantibodies against citrullinated vimentin (i.e., MCV-ACPAs), which are specifically found in patients with RA, directly led to osteoclast differentiation and bone resorption in vitro and in vivo. RA is one of the most common autoimmune diseases, affecting 1% of the worldwide population, and a major trigger for local and systemic bone loss, resulting in joint destruction and increased fracture risk. More than two-thirds of patients with RA develop immune responses against citrullinated proteins, which is highly specific for RA (3). Despite being known for many years, it has been always unclear why these autoantibodies are associated with a more severe disease course, in particular more destructive joint disease. Although the direct link we have demonstrated between autoantibodies and bone loss may not be the only explanation for the more severe disease course of ACPA-positive patients (yet-unidentified differences in the gestalt of inflammation between ACPA-positive and -negative patients cannot be ruled out completely), these data provide an attractive concept of how the breakdown of immune tolerance can damage our skeletal system.

Current concepts suggest a finely balanced interplay between the immune system and bone. These concepts have been driven by clinical observation of bone destruction in RA and other inflammatory diseases. Activation of the innate immune system and production of proinflammatory cytokines, in particular TNF, triggers bone loss by inducing the expression of RANKL, a key osteoclastogenic molecule (21). Moreover, activation of the adaptive immune system, in particular T cell activation, also supports bone destruction. T cell activation, particularly that of the proinflammatory TH17 subset, fosters the expression of RANKL and induces osteoclastogenesis (23). These processes also explain why autoimmune inflammatory diseases such as RA are linked to bone loss.

Although not all RA patients experience bone destruction, others face rapid bone loss and destruction of the joints leading to crippling and functional loss. The clinical heterogeneity of RA with respect to joint damage suggests that there are additional factors that determine bone destruction in patients with arthritis. In fact, the strongest risk factor is the presence of ACPAs. Despite this strong clinical association, the role of autoantibodies on bone has so far been largely neglected. The potential principle that autoantibodies modify bone has been shown in rare cases of autoantibodies against the decoy receptor of RANKL, osteoprotegerin, which caused bone loss in patients with celiac diseases (24). However, so far none of the classical (i.e., frequently observed) autoantibodies has been mechanistically linked to bone loss.

Our study directly links ACPA, a common autoantibody prevalent in RA patients worldwide, to bone loss. ACPA binding to citrullinated vimentin enhanced the differentiation of osteoclast precursors into mature bone-resorbing cells in vitro and in vivo. As a consequence, ACPAs enhanced bone resorption in vitro and in vivo and elicited bone loss in vivo by increasing osteoclast differentiation. Interestingly, the mechanism by which ACPAs trigger bone loss involved TNF-α, the pivotal cytokine in the pathogenesis of RA: MCV-ACPAs induced production of TNF-α by osteoclast precursors, extending previous observations that ACPAs can directly affect cells of the monocyte/macrophage lineage (25–28). For bone, TNF-α is highly important, as it not only facilitates the trafficking of osteoclast precursors from the bone marrow to the lymphoid organs, but also renders them more susceptible to further differentiation into osteoclasts by inducing the receptors of key differentiation factors for osteoclasts, such as M-CSF and RANKL. The net effect of ACPAs is thus a TNF-mediated induction of osteoclastogenesis and bone resorption. Although vimentin affects osteoblast differentiation (29), we could not detect relevant citrullination of vimentin in osteoblasts, and ACPAs also did not affect osteoblast differentiation and bone formation in vitro. We conclude that ACPAs, which are known to emerge years ahead of the clinical onset of RA (30), not only increase susceptibility to RA development, but also appear to disturb bone balance by making individuals more prone to bone resorption. This concept also serves to explain why RA patients already show low bone mass at the onset of disease (31) and why bone damage in RA patients with ACPAs is far higher compared with those without ACPAs.

The observation that osteoclasts contained large amounts of citrullinated vimentin also sheds light on the role of posttranslational modifications, in particular citrullination, in the differentiation of cells of the monocyte lineage. Previous studies have shown that PAD2 and PAD4 are the predominant isoforms expressed in monocytes (32). We observed here that osteoclast precursors shared a similar PAD expression pattern, with PAD2 and PAD4 as the dominant PAD isoforms. In contrast, cells of the osteoclast lineage did not express PAD1 and PAD3. This expression pattern of PADS in osteoclasts was in fact similar to the one found in the inflamed synovial tissue of RA patients (33, 34). Furthermore, during the process of osteoclast differentiation, the PAD expression pattern of cells shifted from PAD4 to PAD2. This observation suggests that PAD2 is the major contributor to protein citrullination in osteoclasts. Interestingly, previous studies have shown that monocye differentiation into macrophages also induces a shift from PAD4 to PAD2 expression, similar to what we found in osteoclasts (32, 35). In contrast, PAD4 has been recently shown to function as an antimicrobial component forming extracellular traps (36). These data indicate that PAD expression and the citrullination pattern of proteins may differ among the various leukocytes subsets and allow for different functional properties of the individual subsets.

Remarkably, calcium has been shown to be a key inducer of PAD, and the calcium-rich environment to which osteoclasts are exposed may foster PAD expression and protein citrullination (37). Indeed, a strong increase in the citrullination of vimentin was observed during osteoclast differentiation, and citrullination occurred at the same region of citrullinated vimentin, which is recognized by the human autoantibody. Vimentin, in fact, has been identified as an important component of the adhesion zone of the osteoclast (38), and it remains to be determined whether its citrullination affects cell function and/or survival. Macrophages, for instance, can secrete vimentin, which facilitates bacterial killing and oxidation product synthesis (39).

In summary, our data showed a disease-relevant link among autoantibody formation, autoimmune disease, and bone loss in humans, which we believe to be novel. Autoantibodies against citrullinated vimentin bind to cells of the osteoclast lineage, foster their differentiation into bone resorbing cells, and promote bone loss. Our data extended current concepts on the interactions of immune system, inflammation, and bone by directly linking ACPA, a key autoantibody in human inflammatory disease, with...
bone loss, leading to joint destruction and functional decline in arthritis. Thus, our findings suggest a link between autoimmunity and the skeleton in human disease.

Methods

Purification of MCV-ACPAs. Samples of serum with very high ACPA response (>1,000 IU/ml) were obtained from 3 RA patients presenting at the Department of Medicine 3 of the University Clinic of Erlangen. ACPA activity was detected with a commercially available ELISA for detection of antibodies against citrullinated vimentin (Oxensor, Diagnostic). Recombinant MCV was conjugated to CNBr-Sepharose (GE Healthcare) (1 mg protein/ml equilibrated sephrose) according to the manufacturer’s instructions and stored at 4°C in PBS with 0.1% BSA. Prior to affinity purification of ACPAs, IgG was purified by affinity chromatography on a protein A column (GE Healthcare). Eluted IgG fractions were immediately neutralized with 1:10 volume of 1 M Tris-buffer (pH 8.0) and dialyzed against PBS (pH 7.2). Each purified IgG fraction was applied to a separate citrullinated vimentin affinity column (1 ml matrix per serum sample) and incubated for 2 hours at 4°C, rotating end over end. The column was washed with 0.5 M NaCl with 0.05% Tween 20 in PBS (pH 7.2), and the unbound fraction was detected with a commercially available ELISA for detection of antibodies against digestion buffer (0.1 M sodium acetate; pH 4.5) with Zebra spin column. 1 ml of this prepared IgG solution was added to a tube containing digested protein was decanted into a new tube, and Protein A was precipitated by adding 1:10 volume of 1 M Tris-buffer (pH 8.0) and dialyzed against PBS (pH 7.2) and concentrated with ultrafiltration units (50K MWCO).

Columns (Pierce) were used to separate undigested IgG from F(ab′)2 fragment and numerous small peptides of the Fc portion. The buffer of the MCV-ACPAs was exchanged against digestion buffer (0.1 M sodium acetate; pH 4.5) with Zebra spin column. 1 ml of this prepared IgG solution was added to a tube containing 100 μl equilibrated Immobilized Pepsin (catalog no. 20343; Pierce) and incubated in a thermostirrer for 4 hours with constant mixing at 600 rpm at 37°C. To separate digested protein from the Immunobilized Pepsin, the solution was centrifuged at 1,000 g for 5 minutes. The supernatant containing digested protein was decanted into a new tube, and Protein A Columns (Pierce) were used to separate undigested IgG from F(ab′)2 fragments. To remove small Fc fragments, the eluted fractions were dialyzed and concentrated with ultrafiltration units (50K MWCO).

Analysis of antibody sialylation. Enzyme-linked lectin-specific ACPA assay (sialACPA ELISA) was used to analyze ACPA sialylation. Neuraminidase treatment was done to cleave selectively sialic acid-containing carbohydrates on the autoantibodies. Sialic acid release was induced by digestion at 25°C for 2 hours with 50 nM neuraminidase cloned from Clostridium perfringens and overexpressed in E. coli (NEB) in 200 μl of 50 μM sodium citrate (pH 6.0).

Synthesis of MCV peptides. Previously published sequences of MCV (17) were used as a template to synthesize overlapping 17-mer peptides, in accordance with Fmoc-chemistry at the Peptide Specialty of Perbio Mimo (Perbio Science Deutschland GmbH). Each peptide had a 12-amino acid residue overlap with the neighboring peptide. The synthesis through the MCV amino acid sequence resulted in 91 peptides with the general formula Biotin-SGS-PEPTIDE-Amide. The N-terminal extension of the peptides (Biotin-SGS) was designed for defined flexibility and to incorporate an affinity tag. Each arginine-containing peptide was synthesized as the citrulline residue variant. Crude fractions after peptide synthesis were purified using high-performance liquid chromatography. Quality and purity of the peptide was assessed by mass spectrometry and analytical high-performance liquid chromatography according to the manufacturer’s instructions (Perbio Science Deutschland GmbH).

Epitope characterization by peptide ELISA. Microtiter plates (Maxisorb) were precoated with 1 μg/ml streptavadin (Perbio Science Deutschland GmbH) in PBS (pH 7.6). After incubation for 2 hours at 25°C, plates were blocked with 1% BSA in PBS for 30 minutes at room temperature. Theses plates were used for binding of the biotinylated peptides/antigens. The biotinylated 17-mer peptides at a concentration of 0.5 μg/ml were also diluted in PBS (pH 7.6) and incubated overnight at 4°C (100 μl/well). In addition to the 91 peptides, biotinylated recombinant MCV, protein A, and rheumatoid factor antigen were used as internal control antigens in the available 5 cavities of a 96-well microtiter plate. Coating and blocking was done as described for peptides. Possible excesses of peptides/antigens were eliminated by washing the cavities with 200 μl/well 0.1% Tween 20 in PBS. Finally, flicking and slapping removed any residual solution. The assay was performed in accordance with the general protocol for the Orgentec ELISA system. In brief, the serum samples were diluted 1:101 in sample buffer (PBS containing BSA and Tween), added to the wells, and then incubated for 30 minutes (100 μl/well). After 3 washing steps (300 μl/well), horseradish peroxidase-conjugated anti-human IgG (Dianova) was added and incubated for 30 minutes (100 μl/well). Visualization was done by incubation with 3,3′,5,5′-tetra-methyl benzidine substrate for 15 minutes (100 μl/well), and the reaction was terminated by adding 50 μl stop solution (0.5 mol/l H2SO4) to each well. Finally, absorbance at 450 nm was determined using an ELISA reader (Rainbow Reader; Tecan). All steps were carried out at room temperature. Background OD was obtained by adding each serum to a well without protein. A positive serum was defined by an OD value more than twice that of background OD (40). Each serum sample was tested in duplicate and to further define the assay characteristics.

Reactivity to citrullinated and noncitrullinated peptides. Citrullin- and respective arginine-containing peptides (denoted by bold X and R, respectively) of vimentin (normal, SAVRASSVPGVRK; citrullinated, SAVRASSVPGVRK), fillagrin (normal, SHQESTGRGSRGRGGRGSR; citrullinated, SHQESTGXXGGRGSRGSRGSR SGGRGSRGSRGSR; collagen (normal, ARGLTGRPGDAD; citrullinated, AGLTXGPGDAD) as well as fibrinogen-derived peptides (normal, RPAPPISGGGYRAR; citrullinated, RPAPPISGGGYXAX) were synthesized by solid-phase peptide synthesis (Fmoc strategy) in the Department of Peptide Chemistry of Eotvos Lorand University (Budapest, Hungary). Biotinylated peptides were bound to NeutriAvidin precoated (5 μg/ml) plates. After adding biotinylated peptides (1 μg/ml), the wells were blocked (40 mM Tris-HCl, 150 mM NaCl, 0.1% Tween, 0.5% BSA), sera were samples were added (1:400 or 1:100), and then plates were incubated for 1 hour at 37°C. After washing, rabbit anti-human IgG conjugated to horseradish peroxidase was added at 1,000 dilution for 1 hour at 37°C. The signal was developed by tetramethylbenzidin (10 mg/ml, diluted in 0.1 M acetate buffer [pH 5.5] and 30% H2O2 for about 5 minutes at room temperature. The reaction was stopped by 4N H2SO4. Absorbance was measured at 450 nm (correction wavelength set at 620 nm) using a Labsystem Multiskan MS spectrophotometer. To analyze our results, an OD ratio (OD of citrullin-containing peptide minus OD of arginine-containing peptide) was calculated and compared between various groups (Kruskal-Walls test).

Mass spectrometry of citrullinated proteins in osteoarticular lineage cells. Cell pellets (1 x 10⁷ cells each) were suspended in 400 μl lysis buffer containing 0.1% Rapigest in 50 mM ammonium bicarbonate and protease inhibitor cocktail (Complete Mini, Roche Diagnostics). The homogenate was sonicated using
a probe tip sonicator (power 50%; Bandelin Sonopuls, Buch & Holm) 3 times for 20 seconds on ice. The homogenate was centrifuged at 9,000 g at 4°C for 5 minutes, and the pellet was discarded. Prepacked PD SpinTrap columns (GE Healthcare) were used for desalting and buffer exchange against 50 mM ammonium bicarbonate. The protein concentration was measured using a NanoDrop spectrophotometer (Thermo Scientific). 100 μg protein from each cell sample was reduced in 200 mM dithiothreitol at 56°C for 30 minutes followed by alkylation by 1M iodoacetic acid for 1 hour at room temperature in darkness. Endoproteasine Lys-C sequencing grade (Roche Diagnostics GmbH) was added at 1:50 enzyme/substrate, and samples were incubated at 37°C overnight. After digestion, the samples were transferred to a Pall Nanosep centrifugal device with Omega membrane MWCO 10 kDa (Pall Corp.). Peptides were cleaned up by ZipTip pipette tips containing C18 media (Millipore) and dried using speed-vac prior to mass spectrometry analysis.

Samples were resuspended in 0.1% formic acid and 1 μg of each was injected onto a Waters NanoAgy UPLC equipped with a nanoAgy 5-μm TRAP C18 180-μm i.d. × 20-mm trapping column and a 1.7-μm BEH130 C18 75-μm i.d. × 150-mm reverse-phase analytical column. The mobile phase consisted of (a) 0.1% formic acid in water and (b) 0.1% formic acid in acetonitrile. The peptides were separated using a gradient of 3%–40% of the latter for the first 90 minutes, then 40%–90% of the latter again for the following 8 minutes. The peptides were analyzed using a Waters Q-ToF Premier mass spectrometer operated in data-dependent mode with 4 components, each acquired for 0.9 s/spectra, 1–3 spectra/peptide. High mass accuracy was achieved by lock-spray using Glu-1-Fibrinopeptide. The raw data were processed using Mascot Distiller version 2.4.0 into .mgf files.

Peptide and protein identification was performed using X!Tandem open source software. The searches were performed against the human SwissProt database, with Lys-C specificity and semi-style cleavage allowed. Mass deviations for precursor ions and for fragment ions were set to 20 ppm and 0.05 Da, respectively. Carbamidomethylation was fixed as a modification, while citrullination (R), deamidation (N, Q), and oxidation (M) were set as variable modifications. Only proteins with expectation value log10 value below ~3 were considered as a positive match.

Osteoclast cultures and resorption tests. Peripheral blood mononuclear cells (PBMCs) were isolated from 10 ml EDTA-blood of healthy donors using a Ficoll gradient (Lyphohlot; BioRad) and incubated in 48-well plates (7.5 × 10^4 cells/well) in α-MEM with 1% PenStrep (both Gibco, Invitrogen). After 3 hours, cells were washed for monocyte enrichment and cultivated for 14 days in α-MEM supplemented with 10% heat-inactivated fetal BSA (Biochrom AG), 1% penicillin/streptomycin (Gibco, Invitrogen), 10 ng/ml MCSF, and submaximal concentrations of 1 ng/ml RANKL (both Quidel). For 3 hours, cells were washed for monocyte enrichment and cultured in 48-well plates with MCSF, RANKL, and TGF-β for 14 days. After the isolation or after various times of culture, proteins were separated by electrophoresis in 10% sodium dodecyl sulfate–polyacrylamide gels and blotted onto polyvinylidine difluoride membranes (Millipore). After blocking with 5% dry milk prepared in PBS containing 0.1% Tween 20, the membranes were subjected to immunoblotting. Antibodies used were as follows: rabbit anti-β-actin antibody (Sigma-Aldrich), chicken anti-citrullinated vimentin antibody, purified human MCV autoantibody (i.e., MCV-ACPs), rabbit anti-PAD2 antibody, rabbit anti-PAD4 antibody, mouse anti-vimentin antibody (all Abcam). Detection was done by respective peroxidase-conjugated antibodies (all Promega) and chemoluminescence reagent (ECL; Thermo Scientific).

Quantitative real-time PCR analysis. PBMCs (7.5 × 10^4 cells/well) were cultivated in 48-well plates with MCSF, RANKL, and TGF-β for 14 days. Directly after the isolation or after various times of culture, total RNA was extracted usingpeqGOLD Trifast (Peqlab) according to the manufacturer’s instructions. RNA was transcribed into cDNA using an oligo(dT) primer and MuLV reverse transcriptase (Roche). Quantitative real-time PCR was performed using SYBR Green I-dTTP (Eurogentec) using the following primer pairs: β2-microglobulin (β2-MG) forward, GATGAGTATGGCTGTCGGTTG; β2-MG reverse, CAATCCAAATGCGGCTACT; PAD2 forward, AGCTCTACATGGTGCAAGT; PAD2 reverse, GGTGTCGCTGGAAGATGGGAG; PAD4 forward, CCCGCAAAGTTGAAAGCCAAC; PAD4 reverse, CTACAGGTACATGAGCACCA. Each sample was analyzed in duplicate and normalized to the level of β2-MG.

Serum parameters. In human serum samples, we measured CTX1 using a commercial kit (ImmunoDiagnostics Systems) based on ELISA. TRAP5b (Quidel) and cathepsin K (Biomedica) were also measured by ELISA. ACPAs were measured by commercial ELISA (Phadia/Thermofisher Scientific), rheumatoid factor by nephelometry (Beckmann Coulter). In murine serum samples, CTX1 (Ratlaps; Nordic Bioscience), osteocalcin (Quidel), and TNF-α (R&D) were measured by commercial ELISAs.

μCT. 10 female Rag1–/– mice were injected i.p. with 50 μg lipopoly saccharide and with 500 μg normal human IgG, 500 μg MCV-ACPs, or PBS. After 4 weeks, mice were sacrificed. The right tibia was weighed and stored in 70% ethanol for μCT analysis (41). μCT analyses were done with a commercially available desktop μCT (μCT35; SCANCO Medical AG) (42). The following acquisition parameters were used: voltage, 40 kV; X-ray current, 250 μA; exposure time, 5,000 ms/projection for 720 projections; matrix, 1024 × 1024; voxel size in reconstructed image, 9 μm. Images were analyzed using a plugin programmed for Amira 4.1.2 (Mercury) for histomorphometric parameters at the metaphyses of the proximal tibiae: ratio of bone volume to total volume, trabecular number, and trabecular thickness (41).

Mouse histology. Mice were treated as described above, and the left tibia was used for histology. Bones were fixed overnight in 4% formalin and decalcified in EDTA (Sigma-Aldrich) until they were pliable. Serial paraffin sections (2 μm) were stained for TRAP for osteoclast detection. All analyses were performed using a microscope (Nikon) equipped with a digital camera and an image analysis system for performing histomorphometry (Osteomeasure; OsteoMetrics).
FACS and murine osteoclast assays. For FACS staining, 1 × 10⁵ murine spleen cells were washed with 1 ml PBS containing 0.1% BSA resuspended in 100 μl FACS buffer and incubated with saturating amounts of PE-Cy7-, FITC-, biotin-, or PE-labeled antibodies against CD11b, CD14 (both BD Bioscience), CD115 (e-Fms, MCSF receptor; Biolegend), and RANK (CD265; Abcam) for 30 minutes at 4°C in the dark. Cells were also stained with isotype control antibody. A FACSCan Flow Cytometer (BD Bioscience) was used for analysis. For osteoclast assays, bone marrow was isolated by flushing femoral bones with complete αMEM. Osteoclast precursors were then isolated from bone marrow–derived cell suspensions using CD11b microbeads (Miltenyi Biotec) according to the manufacturer’s instructions. The purity of isolated monocytes was assessed by flow cytometry analysis using FITC-labeled antibodies against CD11b (Miltenyi Biotec). CD11b+ monocytes were then plated in 96-well plates (2.5 × 10⁴ cells/well) or 48-well plates (5 × 10⁴ cells/well) in αMEM supplemented with 10% fetal calf serum, 30 ng/ml M-CSF, and various doses (0, 1, 5, or 25 ng/ml) of RANKL (all R&D Systems). To examine the contribution of ACPs to osteoclast development, MCV-ACPAs (10 ng/ml) were added to cultures. Medium was changed after 72 hours. To examine the contribution of TNF-α blocking experiments, experiments with 100 ng/ml etanercept, a TNF receptor–Fc fusion protein that also inhibits murine TNF-α, were performed. Osteoclast differentiation was evaluated by staining cells for TRAP using a Leukocyte Acid Phosphatase Kit (Sigma-Aldrich) according to the manufacturer’s instructions.

Statistics. For comparison of multiple groups, 1-way ANOVA with Bonferroni correction was used in case values showed Gaussian distribution. In the absence of Gaussian distribution, the Kruskal-Wallis test with Dunn’s correction was performed. A P value less than 0.05 was considered significant.

Received for publication September 12, 2011, and accepted in revised form March 7, 2012.

Address correspondence to: Georg Schett, Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Krankenhausstrasse 12, Erlangen D-91054, Germany. Phone: 49.9131.85.3363; Fax: 49.9131.85.34770; E-mail: georg.schett@uk-erlangen.de.

Acknowledgments

We thank Fruzsina Babos and Anna Magyar (HAS-ELTE Research Group of Peptide Chemistry, Eötvös Loránd University, Budapest, Hungary) for peptide synthesis, as well as Marlene Gallet (Institut de Génomique Fonctionnelle de Lyon, Lyon, France) for valuable input on the bone resorption assay. This study was supported by the Deutsche Forschungsgemeinschaft (FG 661/TP4 and SPP1468-IMMUNOBONE), the Bundesministerium für Bildung und Forschung (BMBF; project ANCYLOSS), the MASTERSWITCH project of the European Union, the IMI-funded project BTCure, and Agence de Recherche contre le Cancer (ARC). G. Sarmay and E. Szarka are supported by the Hungarian National Development Agency and OTKA (CK80689). U. Harre is a member of the Graduiertenkolleg 1660. D. Georgess is an Early Scientific Researcher recipient from a Marie Curie action (T3Net project). The authors acknowledge the contribution of the PLATIM platform of UMS344/USBiosciences.

Studyparticipation. Studies in animals and humans were reviewed and approved by the ethics committee of the University Clinic of Erlangen. All subjects provided informed consent prior to their participation in the study.

References